Compound · clinical trials

ANS014004 clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 3 trials in our USA, China and Canada registers that name ANS014004 as an intervention. Synced 9 Nov 2026

3Current trials

1Recruiting now

2Lead sponsors

3Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

ANS014004 is named as an intervention in 3 current clinical trials in our USA, China and Canada registers. 1 is recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Avistone Biotechnology Co., Ltd (2). The most-studied condition is Locally Advanced or Metastatic Solid Tumors.

Patient leaflets for ANS014004

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting133%
Not yet open133%
Active, closed133%

Trials by phase

Phase 1267%
Phase 1/2133%

Clinical trials of ANS014004

3 trials

Study	Phase	Status	Lead sponsor	Registers
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors NCT06307795 · Locally Advanced or Metastatic Solid Tumors	Phase 1	Recruiting	Avistone Biotechnology Co., Ltd	USA, China, Canada
A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer NCT07285148 · Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer	Phase 1/2	Not yet open	Beijing Pearl Biotechnology Limited Liability Company	USA
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors NCT06328439 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors	Phase 1	Active, closed	Avistone Biotechnology Co., Ltd	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with ANS014004

5 conditions

Locally Advanced or Metastatic Solid Tumors2 Non-Small Cell Lung Cancer1EGFR Mutation1Metastatic Lung Cancer1MET Alteration1

By country register

Register	Trials	Recruiting
Clinical trials in USA	2	1
Clinical trials in China	2	1
Clinical trials in Canada	1	1

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about ANS014004 trials

How many clinical trials are testing ANS014004?

3 current trials in our USA, China and Canada registers name ANS014004 as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are ANS014004 trials recruiting patients?

Yes. 1 of the 3 trials is recruiting: 1 with sites in USA, 1 with sites in China and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors ANS014004 clinical trials?

Avistone Biotechnology Co., Ltd (2) and Beijing Pearl Biotechnology Limited Liability Company (1). The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ANS014004 works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ANS014004 works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ANS014004 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.